Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Market Cap ₹ 62,251 Cr.
- Current Price ₹ 615
- High / Low ₹ 669 / 386
- Stock P/E 29.1
- Book Value ₹ 135
- Dividend Yield 0.98 %
- ROCE 14.2 %
- ROE 12.1 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 31.3%
Cons
- Stock is trading at 4.56 times its book value
- The company has delivered a poor sales growth of 8.49% over past five years.
- Company has a low return on equity of 11.3% over last 3 years.
- Debtor days have increased from 114 to 147 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,151 | 3,527 | 4,042 | 5,284 | 7,032 | 3,231 | 5,810 | 6,037 | 6,347 | 7,780 | 7,837 | 8,732 | 9,947 | |
2,483 | 2,820 | 3,232 | 3,750 | 4,454 | 2,909 | 4,164 | 4,400 | 4,916 | 5,468 | 5,916 | 6,277 | 6,896 | |
Operating Profit | 668 | 708 | 810 | 1,535 | 2,578 | 322 | 1,646 | 1,637 | 1,432 | 2,312 | 1,921 | 2,454 | 3,051 |
OPM % | 21% | 20% | 20% | 29% | 37% | 10% | 28% | 27% | 23% | 30% | 25% | 28% | 31% |
237 | 51 | 305 | 184 | 174 | 582 | 208 | 598 | 848 | -102 | -144 | 345 | 375 | |
Interest | 126 | 111 | 42 | 43 | 26 | 11 | 64 | 90 | 234 | 71 | 135 | 278 | 327 |
Depreciation | 108 | 117 | 127 | 212 | 221 | 251 | 293 | 358 | 429 | 451 | 479 | 489 | 487 |
Profit before tax | 670 | 531 | 946 | 1,465 | 2,504 | 642 | 1,497 | 1,787 | 1,617 | 1,688 | 1,164 | 2,032 | 2,612 |
Tax % | 2% | 6% | 4% | 13% | 19% | -3% | 27% | 17% | 13% | 13% | 26% | 25% | |
658 | 499 | 904 | 1,271 | 2,038 | 662 | 1,091 | 1,486 | 1,413 | 1,476 | 858 | 1,529 | 1,979 | |
EPS in Rs | 6.42 | 4.87 | 8.83 | 12.42 | 19.90 | 6.47 | 10.66 | 14.51 | 13.80 | 14.42 | 8.38 | 15.11 | 19.55 |
Dividend Payout % | 23% | 31% | 20% | 19% | 16% | 50% | 33% | 24% | 25% | 24% | 30% | 40% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 11% |
TTM: | 28% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | 9% |
3 Years: | 3% |
TTM: | 155% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 9% |
3 Years: | 16% |
1 Year: | 59% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 13% |
3 Years: | 11% |
Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | |
Reserves | 2,455 | 2,809 | 3,528 | 4,423 | 6,174 | 6,516 | 7,643 | 8,467 | 11,158 | 12,642 | 13,138 | 13,538 |
1,284 | 1,786 | 1,586 | 1,450 | 1,223 | 2,940 | 2,872 | 3,583 | 3,695 | 3,920 | 2,665 | 4,825 | |
912 | 855 | 1,027 | 1,362 | 1,424 | 1,489 | 1,546 | 1,519 | 1,597 | 1,799 | 1,835 | 2,099 | |
Total Liabilities | 4,754 | 5,552 | 6,243 | 7,337 | 8,923 | 11,047 | 12,164 | 13,671 | 16,552 | 18,464 | 17,740 | 20,564 |
1,218 | 1,497 | 1,564 | 1,768 | 2,155 | 2,352 | 2,680 | 3,932 | 4,109 | 4,112 | 4,336 | 4,184 | |
CWIP | 312 | 464 | 531 | 367 | 297 | 678 | 659 | 675 | 553 | 570 | 384 | 739 |
Investments | 1,212 | 1,280 | 1,558 | 2,209 | 2,318 | 3,924 | 3,618 | 4,195 | 6,404 | 6,471 | 5,118 | 4,879 |
2,012 | 2,311 | 2,591 | 2,993 | 4,154 | 4,093 | 5,206 | 4,868 | 5,486 | 7,310 | 7,902 | 10,761 | |
Total Assets | 4,754 | 5,552 | 6,243 | 7,337 | 8,923 | 11,047 | 12,164 | 13,671 | 16,552 | 18,464 | 17,740 | 20,564 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
372 | 445 | 878 | 1,084 | 1,954 | 867 | 288 | 581 | 1,181 | 2,227 | 1,272 | 1,078 | |
-817 | -709 | -408 | -577 | -1,016 | -2,480 | 28 | -713 | 55 | -2,714 | 586 | -1,960 | |
522 | 250 | -446 | -387 | -923 | 1,366 | -149 | 65 | -967 | 255 | -1,710 | 827 | |
Net Cash Flow | 76 | -14 | 25 | 120 | 14 | -247 | 167 | -67 | 268 | -231 | 149 | -54 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 71 | 71 | 65 | 73 | 89 | 105 | 79 | 128 | 141 | 89 | 106 | 147 |
Inventory Days | 176 | 169 | 171 | 178 | 127 | 338 | 284 | 288 | 261 | 276 | 245 | 205 |
Days Payable | 100 | 104 | 119 | 148 | 174 | 361 | 173 | 137 | 161 | 175 | 135 | 120 |
Cash Conversion Cycle | 148 | 136 | 117 | 102 | 42 | 82 | 190 | 279 | 241 | 191 | 216 | 232 |
Working Capital Days | 50 | 72 | 61 | 53 | 70 | 74 | 118 | 161 | 138 | 205 | 225 | 208 |
ROCE % | 24% | 15% | 20% | 27% | 38% | 8% | 15% | 16% | 14% | 12% | 10% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Zydus announces IND clearance of a novel Anti-PCSK9 candidate.
- Closure of Trading Window 27 Sep
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 22 Sep
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 Sep - Company is going to participate in an investor conference 'J.P. Morgan India Investor Summit 2023' at Mumbai on Monday, September 25, 2023.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
20 Sep - Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Mar 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Jul 2019Transcript PPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jun 2018Transcript PPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
May 2016Transcript PPT
One of the top five pharmaceutical companies in India.[1]